Isturisa® continues to show promise in Cushing’s disease
New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.
List view / Grid view
New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.
NICE has issued draft guidance that does not recommend chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).